×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
💹
Economics
📊
Experiments
🤖
Agents
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Economics
Status
Showcase
▼
Showcase
Demo
Vision
|
Showcase
←
Home
/
Wiki
/
Disease: ALS Therapeutic Landscape — Programs by Phase and Modality
disease
2,394 words
KG: ent-dise-93f3d65f
section:therapeutics
kind:disease-landscape
topic:als
state:published
Contents
ALS Therapeutic Landscape — Programs by Phase and Modality
Knowledge Graph
Related Hypotheses (27)
Bacterial Enzyme-Mediated Dopamine Precursor Synthesis
Score: 0.59
Purinergic Signaling Polarization Control
Score: 0.71
Mechanosensitive Ion Channel Reprogramming
Score: 0.70
Lipid Droplet Dynamics as Phenotype Switches
Score: 0.67
Multi-Modal CRISPR Platform for Simultaneous Editing and Mon
Score: 0.60
VCP-Mediated Autophagy Enhancement
Score: 0.71
TREM2-Dependent Microglial Senescence Transition
Score: 0.90
TREM2-mediated microglial tau clearance enhancement
Score: 0.80
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
APOE-TREM2 Interaction Modulation
Score: 0.74
Phase-Separated Organelle Targeting
Score: 0.73
Stress Granule Phase Separation Modulators
Score: 0.72
Purinergic P2Y12 Inverse Agonist Therapy
Score: 0.70
Cryptic Exon Silencing Restoration
Score: 0.70
Microglial Purinergic Reprogramming
Score: 0.70
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.70
Extracellular Matrix Stiffness Modulation
Score: 0.69
Cross-Seeding Prevention Strategy
Score: 0.69
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.67
RNA Granule Nucleation Site Modulation
Score: 0.66
Liquid-Liquid Phase Separation Modifier Therapy
Score: 0.66
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.64
Glycine-Rich Domain Competitive Inhibition
Score: 0.64
Gap Junction Hemichannel Modulation for Controlled Mitochond
Score: 0.63
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m
Score: 0.62
Show 22 more
Related Analyses (28)
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · completed
How do non-cell autonomous effects of autophagy dysfunction
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD AD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · archived
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · completed
Show 23 more
Related Experiments (30)
cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95
TDP-43 mutant mouse model cGAS/STING pathway analysis
validation · proposed · Score: 0.90
TDP-43 mitochondrial invasion and mtDNA release in iPSC moto
exploratory · proposed · Score: 0.90
cGAMP biomarker analysis in ALS patient spinal cord samples
clinical · proposed · Score: 0.85
cGAMP biomarker analysis in ALS patient spinal cord samples
exploratory · proposed · Score: 0.80
s:** - Temporal analysis showing mitochondrial defects prece
falsification · proposed · Score: 0.40
Proposed experiment from debate on TDP-43 undergoes liquid-l
falsification · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Blood-Brain Barrier Aging and Neurodegeneration — From Leaka
validation · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Down Syndrome Alzheimer's Disease: Mechanisms and Therapeuti
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Experiment Index
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Multiscale Computational Modeling of Protein Aggregation Kin
validation · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Show 25 more
See Also (15)
Therapeutic Modalities in Neurodegeneration
therapeutic · Pages share 5 hypotheses
Section 147: Telehealth and Remote Monitoring in CBS/PS
therapeutic · Pages share 5 hypotheses
Integrated Stress Response Modulator Therapy in Neurode
therapeutic · Pages share 5 hypotheses
CRISPR Gene Editing for Neurodegeneration
therapeutic · Pages share 5 hypotheses
Cognitive Monitoring Brain-Computer Interfaces for Neur
technology · Pages share 5 hypotheses
PSP Therapeutic Response Monitoring and Biomarkers
mechanism · Pages share 5 hypotheses
Mitochondrial DNA Mutations in Neurodegeneration
mechanism · Pages share 5 hypotheses
Integrated Stress Response in Neurodegeneration
mechanism · Pages share 5 hypotheses
Multimodal Diagnostic Algorithm for CBS and PSP
mechanism · Pages share 5 hypotheses
Neurodegeneration
disease · Pages share 5 hypotheses
A Phase 3, Randomised, Double-blinded, Placebo-controll
clinical · Pages share 5 hypotheses
Digital Therapeutic Platform for Swallowing and Droolin
clinical_trial · Pages share 5 hypotheses
Yoga Therapy for Neurodegeneration
therapeutic · Pages share 4 hypotheses
YAP/TEAD Pathway Modulators for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Wnt Signaling Modulators for Neurodegeneration
therapeutic · Pages share 4 hypotheses
Show 10 more
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)